Pfizer, Syapse to mine real-world cancer data for insight into molecular testing strategies

healthcare data analytics
Syapse’s clinical knowledge base is derived from real-world data sources including electronic health records and molecular lab tests to provide a longitudinal view of a patient’s timeline within the healthcare system. (metamorworks/Getty Images)

Like Amgen and Roche before it, Pfizer has tapped Syapse to help provide precision medicine data gathering and real-world outcomes research for its work in cancer.

But where those collaborations focused on improving drug development and care delivery, Syapse’s latest undertaking will home in on the factors influencing oncologists as they choose different molecular testing and therapy strategies for individual patients.

“We look forward to working with Syapse and its network of health system partners to better understand the treatment journeys of people living with cancer and develop evidence-based insights that can help improve outcomes,” Pfizer Oncology’s chief development officer, Chris Boshoff, M.D., Ph.D., said in a statement.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

In addition to its cancer platform, Syapse’s work with Big Pharma and other health systems has helped it construct a large clinical knowledge base derived from real-world data sources including electronic health records (EHRs) and molecular lab tests to provide a longitudinal view of a patient’s timeline within the healthcare system.

RELATED: Amgen, Merck, Roche get in on Syapse’s $30M round

With its previous benefactor Amgen, Syapse aims to develop analytics to identify clusters of patients within its network that may be a good fit for the drugmaker’s clinical trials, before study sites are chosen. The two companies also hope to build systems to assess outcomes in unmet medical needs and to develop new real-world evidence standards, according to the deal inked this past May.

Meanwhile, its January 2018 partnership with Roche covers four focus areas: developing a learning health system based on real-world evidence, examining the health economics impact of precision medicine on value-based care, connecting insights from EHRs to changes in quality of life and accelerating clinical trial enrollment and patient matching.

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.